[Clinical experience of urological surgery of the patients with hemostatic disorder or hemolytic disease].
This report deals with clinical experience of urologic surgery of patients with hemostatic disorder or hemolytic disease. In the past 5 years from May 1986, 14 operations were conducted in our clinic on 13 patients, consisting of 4 with von Willebrand disease (vWd), 1 with hemophilia B, 4 who had warfarin administration, 3 with essential thrombocythemia and 2 with spherocytosis. Almost all patients were treated hematologically before the urological operations. Except in 1 case, the post-operative course was favorable and under hematologic control. Massive bleeding in 1 case was obviously attributable to over-dosage of warfarin. It is difficult to determine the optimal dose of warfarin under an unstable hemostatic condition during the operation and recovery periods. However, it is possible to carry out urologic surgery for these patients under appropriate hematologic control, and ESWL was safely performed without medical treatment on 3 patients; 1 with vWd, 1 treated with warfarin and 1 with spherocytosis.
Matsumiya
K
K
Department of Medicine, Osaka National Hospital.
Nishimura
K
K
Tsujimura
A
A
Yasunaga
Y
Y
Oka
T
T
Takaha
M
M
Yasui
M
M
Kinoshita
S
S
Matsubuchi
T
T
D000328:Adult; D000368:Aged; D001779:Blood Coagulation Factors / Q000627:therapeutic use; D001804:Blood Transfusion, Autologous; D002648:Child; D002675:Child, Preschool; D005169:Factor VIII / Q000627:therapeutic use; D005260:Female; D005340:Fibrinogen / Q000627:therapeutic use; D002836:Hemophilia B / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D008096:Lithotripsy; D008297:Male; D008875:Middle Aged; D013103:Spherocytosis, Hereditary / Q000150:complications* / Q000628:therapy; D013920:Thrombocythemia, Essential / Q000150:complications* / Q000188:drug therapy; D014570:Urologic Diseases / Q000150:complications / Q000601:surgery*; D014859:Warfarin / Q000009:adverse effects; D014842:von Willebrand Diseases / Q000150:complications* / Q000188:drug therapy
D001779:Blood Coagulation Factors; C026912:cryoprecipitate coagulum; C025667:prothrombin complex concentrates; D014859:Warfarin; D005169:Factor VIII; D005340:Fibrinogen; D006918:Hydroxyurea